Related Experiment Videos
Oral ciprofloxacin therapy for gram-negative bacillary osteomyelitis
The American Journal of Medicine
|April 27, 1987
Summary
Ciprofloxacin effectively treats gram-negative osteomyelitis, showing promise for outpatient care. This study found high cure rates and good tolerance in patients with challenging bone infections.
Area of Science:
- Infectious Diseases
- Orthopedic Surgery
- Pharmacology
Background:
- Gram-negative osteomyelitis often presents treatment challenges with conventional therapies.
- Ciprofloxacin demonstrates potent in vitro activity against common gram-negative pathogens.
- The potential for oral administration suggests feasibility for outpatient management.
Purpose of the Study:
- To evaluate the efficacy and safety of ciprofloxacin for treating gram-negative osteomyelitis.
- To assess the suitability of ciprofloxacin for outpatient treatment protocols.
Main Methods:
- An ongoing study involving 23 patients diagnosed with gram-negative osteomyelitis.
- Patients received ciprofloxacin 750 mg orally twice daily for 1.5 to six months.
- Diagnosis confirmed by bone culture or arthrocentesis; pathogen identification and susceptibility testing performed.
Main Results:
- All 14 patients who completed therapy achieved a clinical cure, with a mean follow-up of 6.1 months.
- Radiological and clinical resolution observed in most patients currently undergoing treatment.
- Ciprofloxacin demonstrated excellent activity against gram-negative bacilli, including Pseudomonas species.
Conclusions:
- Ciprofloxacin therapy is highly effective and well-tolerated for gram-negative osteomyelitis.
- The oral route and favorable outcomes support its use in outpatient settings.
- Further investigation is warranted to establish ciprofloxacin as a standard treatment.